Related Experiment Video

Updated: Jan 31, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.1K

Pulmonary aspiration in preschool children with cystic fibrosis

D Clarke1,2, I Gorman3,4, F Ringholz1,2

  • 1National Children's Research Centre, Crumlin, Dublin 12, Ireland.

Respiratory Research
|December 19, 2018
PubMed

Insights

Pulmonary aspiration of gastric refluxate (PAGR) was studied in preschool children with Cystic Fibrosis (CF). Elevated pepsin in broncho-alveolar lavage fluid was found in some CF patients but not linked to inflammation or symptoms.

Area of Science:

  • Pediatric Pulmonology
  • Gastroenterology
  • Cystic Fibrosis Research

Background:

  • Pulmonary aspiration of gastric refluxate (PAGR) is linked to lung inflammation in school-aged children with Cystic Fibrosis (CF).
  • This study investigated whether PAGR is also present and associated with lung issues in preschool children with CF.

Discussion:

  • Pepsin, a marker of gastric refluxate, was measured in broncho-alveolar lavage (BAL) fluid of preschool CF patients and controls.
  • Elevated pepsin levels were detected in a subset of preschool children with CF.
  • However, these elevated pepsin levels did not correlate with pulmonary infection, inflammation, or respiratory/gastrointestinal symptoms in this age group.

Key Insights:

  • Gastric aspiration may occur in preschool children with CF, indicated by pepsin in BAL fluid.
  • Unlike older children, PAGR in preschool CF patients does not appear to be associated with active lung inflammation or clinical symptoms.
  • This suggests a potentially different relationship between gastric aspiration and lung health in early childhood CF.

Outlook:

  • Further research is needed to understand the long-term implications of PAGR in preschool CF patients.
  • Investigating the mechanisms underlying the lack of association with inflammation in this age group is crucial.
  • This could inform targeted monitoring and early intervention strategies for young CF patients.

More Related Videos

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

573
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

1.8K

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
871
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
539
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
295
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
953
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.5K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
614